SOURCE: Brean Murray & Co., Inc

August 31, 2005 12:36 ET

Brean Murray & Co., Inc. Adds to Strong Biotechnology Research Franchise

NEW YORK, NY -- (MARKET WIRE) -- August 31, 2005 -- Andrew S. Fein has joined Brean Murray & Co., Inc. as a Senior Biotechnology Analyst, Senior Vice President.

Mr. Fein is a proven stock picker and enjoys a strong reputation on the stocks he follows. He comes to Brean Murray from the healthcare/biotech research and investment banking firm, Leerink Swann, where he gained Institutional Investor poll recognition. Prior research affiliations include J. P. Morgan, where he was an integral part of a well-known and top-ranked biotechnology team, and Deutsche Bank.

His education provides a rare combination of industry knowledge and research excellence. He graduated with a double major in Biology and History from Yale, where he graduated Summa Cum Laude and Phi Beta Kappa. Subsequently, he completed part of the medical school curriculum at NYU before redirecting his efforts to an equity analyst career.

"Expanding our research team with someone of Andrew's distinction continues the significant growth strategy underway at Brean Murray and furthers our already strong franchise in biotech," said William McCluskey, CEO of Brean Murray.

About Brean Murray & Co., Inc.

Brean Murray & Co., member NYSE and NASD, has served growth companies and investors for over three decades. It is a full service, research-driven securities firm, dedicated to delivering the highest quality investment banking services and research ideas to its institutional clients. The firm's services include equity research, investment banking, institutional sales and trading, syndicate, and asset management. The firm's clients include institutional investors, high net worth individuals and corporations who use our capital markets services to take advantage of compelling market opportunities.

Contact Information

  • Contact:
    Gary Giblen
    Brean Murray & Co., Inc.